LATEST DEVELOPMENT IN LUNG CANCER IMUNOTHERAPY & INSIGHTS TO THE DAILY CLINICAL PRACTICE
|
|
- Agatha White
- 5 years ago
- Views:
Transcription
1 LATEST DEVELOPMENT IN LUNG CANCER IMUNOTHERAPY & INSIGHTS TO THE DAILY CLINICAL PRACTICE Solange Peters MD-PhD Head Medical Oncology and Thoracic Clinic Oncology Department Lausanne University Hospital
2 DISCLOSURE SLIDE I have received education grants, provided consultation, attended advisory boards and/or provided lectures for the following organizations: Amgen, AstraZeneca, Boehringer- Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Sharp and Dohme, and Merck Serono, Pfizer, Regeneron and Takeda. I declare no conflict of interest.
3 NSCLC Outcome: 8th TNM
4 Lung cancer facts Lung cancer is characterized by a strongly immunosuppressive environment We have been enrolling thousands of patients in strictly negative vaccine trials Lung tumors display ~200 nonsynonymous mutations per tumor. Lung cancers from smokers have 10 times as many somatic mutations as those from non smokers. Vogelstein, Science 2013 Lawrence, Nature 2013
5 Barriers to T-cell activity in solid tumors
6 Approvals in NSCLC Nivo (2L SQ) 1 Nivo (2L SQ) 2 Checkpoint Inhibitors in Thoracic Cancers: Nivo (2L NSQ) Nivo ± ipi (SCLC) Checkmate 032 Pembro (SCLC) KEYNOTE-028 Pembro (Meso) KEYNOTE-028 Nivo (2L) 3 Pembro (2L PD-L1+) 1 Pembro (2L PD-L1+) 2 Nivo (2L NSQ) 2 Key Milestones Pembro (1L PD-L1+) Nivo (Meso) NivoMes Avel (Meso) JAVELIN Solid Tumor Pembro (Thymic) NCT Atezo (2L) 1 Atezo (SCLC) NCT U.S. Food and Drug Administration. 2. European Medicines Agency. 3. ONO Pharmaceutical Co., Ltd. 4. Merck [press release]. December 19, Pembro (1L PD-L1+) 4 Pembro (2L PD-L1+) 4 Pembro (1L PD-L1+) 2 Pembro + chemo (1L) 1 Atezo (2L) Nivo ± ipi (Meso) MAPS2 Durva (Stage IIIB) 1 Nivo ± ipi TMB (SCLC) Checkmate 032 Nivo + ipi (Meso) INITIATE Clinical data in other thoracic tumors 6
7 NIVO+IPI Lung-MAP DURVA + Treme Arctic AVEL + utomilumab JAVELIN Medley OX40 agonists + utomilumab NCT DURVA + AZD9291 CAURAL NIVO+IPI Checkmate 722 Lung-MAP AVEL + utomilumab JAVELIN Medley OX40 agonists + utomilumab NCT NIVO + Cx Checkmate 722 DURVA + AZD9291 CAURAL Later lines Second line First line NIVO Checkmate 077 Checkmate 078 Checkmate 870 Checkmate 153 DURVA ATLANTIC NIVO Checkmate 017 Checkmate 057 Checkmate 077 ( 2L) Checkmate 078 ( 2L) Checkmate 870 ( 2L) Checkmate 384 Checkmate 153 ( 2L) Checkmate 907 PEMBRO KEYNOTE-010 ATEZO POPLAR OAK FIR ATEZO + Cx IMpower 130 IMpower 131 IMpower 132 IMpower 150 PEMBRO + Cx KEYNOTE-021 KEYNOTE-189 KEYNOTE-407 NIVO+Cx Checkmate 012 Checkmate 227 Checkmate 568 Checkmate 722* ONO PEMBRO KEYNOTE-024 KEYNOTE-042 NIVO Checkmate 026 DURVA + TREME + Cx POSEIDON NCT NIVO + erlo or Cx or NIVO+Ipi in EGFR M+ Checkmate 012 Checkmate 370 ATEZO + erlo or alectinib NCT PEMBRO + crizotinib NCT PEMBRO + MK-1308 NCT DURVA+ Treme MYSTIC NEPTUNE NCT NIVI/PEMBRO+ epacadostat ECHO202 ECHO204 NIVO+Ipi Checkmate 012 Checkmate 227 Checkmate 817 Checkmate 592 Checkmate 955 Checkmate 568
8 Data show a consistent OS benefit in 2 nd line
9 Our lessons from late lines clinical trials Histological subtype does not matter, but smoking does Anti PD(L)-1 response is rapid and rarely non conventional PD-L1 positivity allows enrichment Observed OS effect is stronger than PFS : non-proportional HRs Activity is present in the brain Anti PD(L)-1 has manageable toxicities Anti PD(L)-1 is better tolerated than docetaxel Anti PD(L)-1 results in better PROs than chemotherapy In NSCLC, a plateau and long term survival are observed
10 OS (%) y OS, 42% 5-Year Estimates of OS Phase 1 Nivolumab Median OS (95% CI), mo Overall (N = 129) 9.9 (7.8, 12.4) 2 y OS, 24% 3 y OS, 18% 5 y OS, 16% Years No. at Risk Brahmer, AACR 2017 Leigh, ASCO 2017 Plateau and long term survival 3-Year Estimates of OS Phase 1 pembrolizumab
11 Are we treating NSCLC patients as in clinical trials? Treatment patterns for a population of Canadian patients with metastatic NSCLC (Ontario, through multiple linked provincial databases) Sacher, Cancer 2015 Stinchcombe and Socinski. Oncologist 2008
12 First line platinum doublet chemotherapy is a challenging Treatment N PD-L1+ % competitor RR % PFS (median) months OS (median) PARAMOUNT (NSCC) 359? E4599 (NSCC) 434? Squire (SCC) 545?
13 ORR (%) PD-L1 Cutoffs: ORR by PD-L1 expression levels in 1L NSCLC 50 CheckMate 012 KN-001 BIRCH Durva JAVELIN Solid Tumor 58,3 (NCT ) , ,4 21, , ,2
14 Key eligibility criteria: Stage IV or recurrent NSCLC CheckMate 026: Nivolumab vs Chemotherapy No prior systemic therapy for advanced disease No EGFR/ALK mutations sensitive to available targeted inhibitor therapy 1% PD-L1 expression a CNS metastases permitted if adequately treated at least 2 weeks prior to randomization Randomize 1:1 Stratification factors at randomization: PD-L1 expression (<5% vs 5%) a Histology (squamous vs non-squamous) Nivolumab 3 mg/kg IV Q2W n = 271 Chemotherapy (histology dependent) b Maximum of 6 cycles n = 270 Tumor scans Q6W until wk 48 then Q12W Disease progression Primary endpoint: PFS ( 5% PD-L1+) d Secondary endpoints: PFS ( 1% PD-L1+) d a Dako 28-8 validated; archival tumor samples obtained 6 months before enrollment were permitted; PD-L1 testing was centralized b Squamous: gemcitabine 1250 mg/m 2 + cisplatin 75 mg/m 2 ; gemcitabine 1000 mg/m 2 + carboplatin AUC 5; paclitaxel 200 mg/m 2 + carboplatin AUC 6; Non-squamous: pemetrexed 500 mg/m 2 + cisplatin 75 mg/m 2 ; pemetrexed 500 mg/m 2 + carboplatin AUC 6; option for pemetrexed maintenance therapy c Permitted 14 if crossover eligibility criteria met, including progression confirmed by independent radiology review d Tumor response assessment for PFS and ORR per RECIST v1.1 as determined by independent central review OS ORR d Disease progression or unacceptable toxicity Crossover nivolumab c (optional)
15 PFS (%) PD-L1 >5% CheckMate 026 Median PFS, months (95% CI) Months Nivolumab n = (3.0, 5.6) Nivolumab Chemotherapy Chemotherapy n = (5.4, 6.9) 1-year PFS rate, % No. of patients at risk: Nivolumab Chemotherapy Socinsky, ESMO 2016 HR = 1.15 (95% CI: 0.91, 1.45), P = All randomized patients ( 1% PD-L1+): HR = 1.17 (95% CI: 0.95, 1.43)
16 KEYNOTE-024 Pembrolizumab vs chemo in high PD-L1 Key Eligibility Criteria Untreated stage IV NSCLC PD-L1 TPS 50% ECOG PS 0-1 No activating EGFR mutation or ALK translocation No untreated brain metastases No active autoimmune disease requiring systemic therapy Key End Points Primary: PFS (RECIST v1.1 per blinded, independent central review) Secondary: OS, ORR, safety Exploratory: DOR R (1:1) N = 305 Pembrolizumab 200 mg IV Q3W (2 years) Platinum-Doublet Chemotherapy (4-6 cycles) PD a Pembrolizumab 200 mg Q3W for 2 years
17 P F S, % Assessed per RECIST v1.1 by blinded, independent central review. Data cut-off: May 9, Events, n Median, mo HR (95% CI) % 70 50% 48% 60 15% No. at risk PD-L1 >50%: Keynote 024 Time, months Pembro Chemo ( ) Brahmer, ASCO 2017 P <0.00 1
18 PD-L1 >50%: Keynote 024: updated OS Brahmer, WCLC 2017
19 EMA approval: 12/2016 Pembrolizumab frontline
20 Do we have good biomarkers in hands for NSCLC? Tissue is strongly limited in NSCLC Almost all trials so far in NSCLC have shown a positive relationship between clinical benefit from PD1 or PD-L1 inhibitors and PD-L1 expression Most data are presented for a cut off value rather than by cohorts determined by ranges of expression.
21 The dilemma of predictive PD-L1 IHC 5 drugs, each with its own PD-L1 IHC assay Drug Antibody Platform TC IC Nivolumab 28-8 clone Dako + Pembrolizumab 22C3 clone Dako + Atezolizumab SP142 clone Ventana + + Durvalumab SP263 clone Ventana + Avelumab - Dako + 4 antibodies 2 immunostainer platforms Different cut-offs (<1%, 5%, 10%, 25%, 50%) Different scoring: Tumor cells +/- Immune cells
22 Comparison studies using trial-validated assays German Ring study NCCN Study AZ500 study IASLC Blueprint study Scheel et al. Mod Pathol 2016; Rimm D et al (in press), Ratcliffe MJ et al, CCR 2017 epub, Hirsch FR et al, JTO 2017; The 28-8, 22C3 and SP263 assays are technically similar The SP142 assay is different We can use ONE assay and read it for prescription of multiple drugs. This defines a need for harmonization! Cave: about 50% of 27 LDTs showed discordant results - Kappa < 0.75
23 High TMB May Influence the Immune-Mediated Tumor cells with high TMB 1,2 Tumor cell Anti-Tumor Response may have high neoantigen load 1,2 which can lead to increased immune and anti-tumor response 2-5 NK cell CD8+ T cell 1. Schumacher TN, Schreiber RD. Science. 2015;348(6230): Kim JM, Chen DS. Ann Oncol. 2016;27(8): Liontos M et al. Ann Transl Med. 2016; 4(14): Sharma P, Allison JP. Science. 2015;348(6230): Giannakis M et al. Cell Rep. 2016;15: Tumor The hypothesis that high TMB increases the immunogenicity of tumors makes them a rational target for treatment with I-O therapies 1,2
24 PFS (%) High TMB Median PFS, months (95% CI) No. at Risk by Time Months Nivolumab Chemotherapy PFS by TMB Subgroup Nivolumab Chemotherapy n = 47 n = (5.5, NA) 5.8 (4.4, 9.1) HR = 0.62 (95% CI: 0.38, 1.00) Nivolumab Chemotherapy Low/Medium TMB Median PFS, months (95% CI) Nivolumab Chemotherapy n = 111 n = (2.8, 5.4) 6.9 (5.6, 8.8) HR = 1.82 (95% CI: 1.30, 2.55) Chemotherapy Nivolumab Months
25 TMB by F1 (somatic mutations per Mb) TMB by WES (missense mutations) How to assess TMB? TMB Concordance Between F1 and WES There was no association between TMB and PD-L1 expression (in these patients with 1% PD-L1 tumor expression) TMB WES median 148 WES bridged to F In silico/vitro F1 panel simulation correlates with WES (n=312) - TMB calculated from WES was highly correlated with TMB outputs from F1 (Spearman s r = 0.9) (n=44)
26 Can it be performed in liquid biopsies?
27 Comparing TMB across matched tumor tissue and ctdna? TMB TMB (including potentially functional variant) Median (muts/mb) TMB<15 (n) TMB>15 (n) Median (muts/mb) TMB<15 (n) TMB>15 (n) Matched-Paired Concordance Tissue ctdna Test Mean of Differences 95% CI P [-15.2, -5.0] < [-0.4, -0.0] Paired T-test [-19.6, -10.0] < Andrew A. Davis, et al. JCO , no. 15_suppl - published online before print [-0.4, -0.1] <0.001 Correlation Coefficient Pearson Correlation P Coefficient of Determination R= R 2 = R= R 2 = patients with NSCLC (53), breast cancer (34), and other solid tumors (10) with paired tissue (FoundationOne) and ctdna (Guardant360) Tissue coverage ~ million bp; ctdna coverage 78, ,000 bp P
28 OAK (atezolizumab) serum TMB
29 Plasma ctdna release: affected by many factors n=223 Tumor type Tumor stage Blood-brain barrier These can all impact plasma ctdna release Sci Transl Med. Feb 19, 2014; 6(224): 224ra24 frequency of cases with detectable ctdna (%) 100% 80% 60% 40% 20% 0% n=355 P<0.001 n=218 Brain 单纯脑转移 metastasis Other 其它转移部位 metastasis
30 Yarchoan, NEJM 2017 Mutation burden across diseases
31 Biomarkers signatures applied for frontline IO? PD-L1 IHC Mutational burden or surrogate Microsatellite instability Surrogates of immune response Immune cells Gene signature Rizvi NA, et al. Science. 2015;348: Fehrenbacher L, et al. Lancet 2016;387: McGranahan N, et al. Science. 2016;351:
32 Routy et al., Science 359, (2018) 5 January 2018
33 PFS by fecal diversity
34 Maximal heterozygosity at HLA-I loci improved overall survival on immunotherapy compared with patients who were homozygous for at least one HLA locus.
35 Therapeutic Approaches to engage the immune system Activation/priming of T cells mab against PD-1, PD-L1, CTLA-4 IL-2 IL-12 Agonists for CD137, OX40, CD27 Presentation of tumorassociated antigens by APC Vaccines IFN-α GM-CSF Release of tumor-associated antigens Chemotherapy Radiotherapy Targeted therapy Lymph node Tumor Blood vessel Migration of activated T cells to the tumor via blood vessels Infiltration of T cells into the tumor mab against VEGF/VEGFR Recognition and killing of tumor cells mab against PD-1, PD-L1, IDO, LAG-3 Combinations across modalities might allow to drive tumour immunogenicity
36 Combining immunotherapy and chemotherapy Immunotherapy can modify tumor micro-environment increasing sensitivity to chemotherapy Reduced support to cancer cells (effect on MDSC and macrophages) Reprogrammed tumor vasculature Chemotherapy can boost the immune response Immunogenic cell death Depletion of myeloid cells & Tregs, influx of TILs, inflammation Leisha A. Emens, and Gary Middleton Cancer Immunol Res 2015;3: Lorenzo Galluzzi et al. Cancer Immunol Res 2016 Peters, ASCO 2017
37 Rational for Anti-angiogenesis & Immunomodulation combination c n O y g o l o l a c i Angiogenic factors play in influencing lymphocyte trafficking nacross endothelia into i l C tumor deposits n i s s a l VEGF has profound effects on immune regulatory cell function c r e t By inhibiting dendritic cell maturation and antigen presentation s a By inhibiting T-cell responses (upregulation PD-L1, PD-L2, IDO-1, IL-6, IL-10 ) M O By inducing proliferation of regulatory T cells M S By favoring accumulation of myeloid-derived suppressor cells E O S E h t 17
38 38 Stage IV or recurrent metastatic Non-squamous NSCLC Chemotherapy-naive a Tumour tissue available for PD-L1 & Teff testing Any PD-L1 IHC Stratification factors: Sex PD-L1 IHC expression Liver metastases N = 1202 IMpower150 study design IMpower150 evaluates the addition of atezolizumab to chemotherapy ± bevacizumab in chemotherapy-naive patients with non-squamous NSCLC R 1:1:1 Arm A Atezolizumab b + Carboplatin c + Paclitaxel d 4 or 6 cycles Arm B Atezolizumab b + Carboplatin c + Paclitaxel d + Bevacizumab e 4 or 6 cycles Arm C Carboplatin c + Paclitaxel d + Bevacizumab e 4 or 6 cycles Maintenance therapy (no crossover permitted) Atezolizumab b Atezolizumab b + Bevacizumab e Bevacizumab e Treated with atezolizumab until PD by RECIST v1.1 or loss of clinical benefit AND/OR Treated with bevacizumab until PD by RECIST v1.1 Teff, T-effector; WT, wild-type. a Patients with a sensitising EGFR mutation or ALK translocation must have disease progression or intolerance of treatment with one or more approved targeted therapies. b Atezolizumab: 1200 mg IV q3w. c Carboplatin: AUC 6 IV q3w. d Paclitaxel: 200 mg/m 2 IV q3w. e Bevacizumab: 15 mg/kg IV q3w. Reck M, et al. IMpower150 PFS analysis. Survival follow-up
39 4 cycles of platin? Median, 6.8 mo (95% CI: 6.0, 7.1) PFS in EGFR and ALK WT Landmark PFS, % Median, 8.3 mo (95% CI: 7.7, 9.8) Arm C: bev + CP Arm B: atezo + bev + CP 6-month 56% 67% 12-month 18% 37% HR, (95% CI: 0.517, 0.737) P < Minimum follow-up: 9.5 mo
40 Keynote-024 PD-L1 > 50%: pembrolizumab mpfs 10m 1yr PFS 48% Did we define new IO standards for all advanced untreated NSCLC patients? Monotherapy IO/IO IO/chemo Phase 1/2 Ipi/Nivo Terme/Durva (Mystic PFS negative) Frontline therapy for naive Advanced NSCLC IMPower 150 All PD-L1 non-squamous, bevacizumab eligible pembrolizumab + chemo + bev mpfs 8m 1yr PFS 37% 20-30% 40% Squamous PD-L1 0-49%? 20-80%?
41 Mystic phase 3 trial
42 Keynote 189
43 Checkmate 227
44 Impower 131
45 The pace of clinical trials in NSCLC has clearly outstripped our understanding of specific immunogenicity and our ability for a rational selection of patients
46 Target Overview of the PD-1/L1 combo trials in lung cancer Numbers of Trials Using Common Combo Strategies: 1. Anti-CTLA-4 agents: Chemotherapies: Radiotherapies: 15 THERAPIES AGAINST 61 DIFFERENT TARGETS ARE BEING COMBINED WITH ANTI-PD1/L1 AGENTS 4. Chemoradiotherapy combos: 10 Chemotherapy 48 Chemoradiothera py 10 Radiotherapy 15 CTLA-4 48 Courtesy of Cancer Research Institute Part 3
47 Resistance mechanisms Impaired recognition, insensitivity to T cell effectors and trafficking
48 Thanks for your attention
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationIMMUNE CHECKPOINT BLOCKADE FOR NSCLC. Marina Chiara Garassino
IMMUNE CHECKPOINT BLOCKADE FOR NSCLC Marina Chiara Garassino Cells of the Immune System Innate immune system: Involving proteins (chemokines and cytokines) and cells, is considered to be the first line
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationEmerging biomarkers for immunotherapy in lung cancer
Emerging biomarkers for immunotherapy in lung cancer Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Aberdeen, UK Why Do We Need Biomarkers for Immunotherapy?
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationesmo.org ESMO IMMUNO-ONCOLOGY CONGRESS 2017
ESMO IMMUNO-ONCOLOGY CONGRESS 2017 Primary PFS and safety analyses of a randomised Phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationStrengths and Weaknesses of PD-L1 testing: Pathology perspective
Strengths and Weaknesses of PD-L1 testing: Pathology perspective Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Foresterhill, Aberdeen Disclosures
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationClinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors
Clinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors ESP/ESMO Marina Chiara GARASSINO Amsterdam 2017 September, 4th 29 European Congress of Pathology Disclosures BMS ROCHE
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationIMUNOTERAPIA NO CÂNCER DE PULMÃO: PRINCÍPIOS
IMUNOTERAPIA NO CÂNCER DE PULMÃO: PRINCÍPIOS Dr. Gilberto de Castro Junior Professor Colaborador Livre-Docente Faculdade de Medicina da USP. Serviço de Oncologia Clínica - Instituto do Câncer do Estado
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationUpdates in Lung Cancer
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationUpdates in Lung Cancer. J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationWhat is new in Immunotherapy, Biomarkers and Side Effects
What is new in Immunotherapy, Biomarkers and Side Effects Prof Dr Christian Rolfo, MD, PhD, MBA Director of Phase I Early Clinical Trials Unit Director of Clinical Trial Management Program Oncology Department
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More information